1 EZETROL (ezetimibe) 10 mg tablet
EZETROL (ezetimibe) 10 mg tablet

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet of EZETROL for oral administration contains 10 mg ezetimibe.
Excipients with known effect
Each 10 mg tablet contains 55 mg lactose monohydrate.
For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM
EZETROL 10 mg is a white to off white capsule shaped tablet debossed with 414 on one side and plain on the other. Dimensions are 8.13 mm x 4.06 mm.

4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Primary Hypercholesterolaemia
EZETROL, administered with an HMG-CoA reductase inhibitor (statin) or alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG) and to increase high-density lipoprotein cholesterol (HDL-C) in adult and adolescent (10 to 17 years of age) patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.

Homozygous Familial Hypercholesterolaemia (HoFH)
EZETROL, administered with a statin, is indicated for the reduction of elevated total-C and LDL-C levels in adult and adolescent (10 to 17 years of age) patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis).

Homozygous Sitosterolaemia (Phytosterolaemia)
EZETROL is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.

4.2 Dose and method of administration
Dose
The patient should be on an appropriate lipid-lowering diet and should continue on this diet during treatment with EZETROL.
The recommended dose of EZETROL is 10 mg once daily, used alone or with a statin. EZETROL can be administered at any time of the day, with or without food.

Elderly population
No dosage adjustment is required for elderly patients (see section 5.2).

Renal impairment/Chronic Kidney Disease
Monotherapy
In patients with renal impairment, no dosage adjustment of EZETROL is necessary (see section 5.2).
Combination Therapy with Simvastatin
In patients with mild renal impairment (estimated GFR ≥60 mL/min/1.73 m$^3$), no dosage adjustment of EZETROL or simvastatin is necessary. In patients with chronic kidney disease and estimated glomerular filtration rate <60 mL/min/1.73 m$^3$, the dose of EZETROL is 10 mg and the dose of simvastatin is 20 mg once a day in the evening. In such patients, the use of higher doses of simvastatin should be closely monitored. (see sections 4.4, 5.1 and 5.2).

Hepatic impairment
No dosage adjustment is required in patients with mild hepatic insufficiency (Child Pugh score 5 to 6). Treatment with ezetimibe is not recommended in patients with moderate (Child Pugh score 7 to 9) or severe (Child Pugh score >9) liver dysfunction. (see sections 4.4 and 5.2).

Paediatric population
Children and adolescents ≥10 years: No dosage adjustment is required (see section 5.2).
Children <10 years: Treatment with EZETROL is not recommended.

Co-administration with bile acid sequestrants
Dosing of EZETROL should occur either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant.

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

When EZETROL is to be administered with a statin, please refer to the data sheet for that particular statin.

4.4 Special warnings and precautions for use
When EZETROL is to be administered with a statin, please refer to the data sheet for that particular statin.

Liver Enzymes
In controlled co-administration trials in patients receiving EZETROL with a statin, consecutive transaminase elevations (≥3 X the upper limit of normal [ULN]) have been observed (see section 4.8). When EZETROL is co-administered with a statin, liver function tests should be performed at initiation of therapy and according to the recommendations of the statin, and periodically thereafter. If an increase in ALT or AST ≥3 X the ULN persists the statin dose should be reduced or the statin withdrawn.

In the IMProved Reduction of Outcomes: Vyttorin Efficacy International Trial (IMPROVE-IT), 18,144 patients with CHD were randomized to receive ezetimibe/simvastatin 10/40 mg daily (n=9067) or simvastatin 40 mg daily (n=9077). During a median follow-up of 6.0 years, the incidence of consecutive elevations of transaminases (≥3 X ULN) was 2.5% for ezetimibe/simvastatin and 2.3% for simvastatin. (see section 4.8).

In a controlled clinical study in which over 9000 patients with chronic kidney disease were randomised to receive EZETROL 10 mg combined with simvastatin 20 mg daily (n=4650) or placebo (n=4620) (median follow-up period of 4.9 years), the incidence of consecutive elevations of
transaminases (>3 X ULN) was 0.7% for EZETROL combined with simvastatin and 0.6% for placebo (see section 4.8).

Skeletal Muscle
In clinical trials, there was no excess of myopathy or rhabdomyolysis associated with EZETROL compared with the relevant control arm (placebo or statin alone). However, myopathy and rhabdomyolysis are known adverse reactions to statins and other lipid-lowering medicines. In clinical trials, the incidence of CPK >10 X ULN was 0.2% for EZETROL vs 0.1% for placebo, and 0.1% for EZETROL co-administered with a statin vs 0.4% for statins alone.

In post-marketing experience with EZETROL, cases of myopathy and rhabdomyolysis have been reported regardless of causality. Most patients who developed rhabdomyolysis were taking a statin prior to initiating EZETROL. However, rhabdomyolysis has been reported very rarely with EZETROL monotherapy and very rarely with the addition of EZETROL to agents known to be associated with increased risk of rhabdomyolysis. All patients starting therapy with EZETROL should be advised of the risk of myopathy and told to report promptly any unexplained muscle pain, tenderness or weakness. EZETROL and any statin that the patient is taking concomitantly should be immediately discontinued if myopathy is diagnosed or suspected. The presence of these symptoms and a creatine phosphokinase (CPK) level >10 times the ULN indicates myopathy.

In IMPROVE-IT, 18,144 patients with CHD were randomized to receive ezetimibe/simvastatin 10/40 mg daily (n=9067) or simvastatin 40 mg daily (n=9077). During a median follow-up of 6.0 years, the incidence of myopathy was 0.2% for ezetimibe/simvastatin and 0.1% for simvastatin, where myopathy was defined as unexplained muscle weakness or pain with a serum CK ≥10 times ULN or two consecutive observations of CK ≥5 and <10 times ULN. The incidence of rhabdomyolysis was 0.1% for ezetimibe/simvastatin and 0.2% for simvastatin, where rhabdomyolysis was defined as unexplained muscle weakness or pain with a serum CK ≥10 times ULN with evidence of renal injury, ≥5 X ULN and <10 X ULN on two consecutive occasions with evidence of renal injury or CK ≥10,000 IU/L without evidence of renal injury. (see section 4.8).

In a clinical trial in which over 9000 patients with chronic kidney disease were randomised to receive EZETROL 10 mg combined with simvastatin 20 mg daily (n=4650) or placebo (n=4620) (median follow-up 4.9 years), the incidence of myopathy/rhabdomyolysis was 0.2% for EZETROL combined with simvastatin and 0.1% for placebo (see section 4.8).

Hepatic Insufficiency
Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe hepatic insufficiency, EZETROL is not recommended in these patients (see section 5.2).

Fibrates
The safety and efficacy of ezetimibe administered with fibrates have not been established; therefore, co-administration of EZETROL and fibrates is not recommended (see section 4.5).

Cyclosporine
Caution should be exercised when initiating ezetimibe in the setting of cyclosporine. Cyclosporine concentrations should be monitored in patients receiving EZETROL and cyclosporine (see section 4.5).
**Anticoagulants**

If EZETROL is added to warfarin, another coumarin anticoagulant, or fluindione, the International Normalised Ratio (INR) should be appropriately monitored (see section 4.5).

**Paediatric Use**

Safety and effectiveness of EZETROL co-administered with simvastatin in patients 10 to 17 years of age with heterozygous familial hypercholesterolaemia have been evaluated in a controlled clinical trial in adolescent boys and in girls who were at least one year post-menarche. Adolescent patients treated with EZETROL and up to 40 mg/day simvastatin had an adverse experience profile similar to that of adult patients treated with EZETROL and simvastatin. However, elevations of CPK (≥10 X ULN) occurred in two patients (2%) treated with EZETROL co-administered with simvastatin and in zero patients treated with simvastatin alone. No cases of myopathy were reported. In this controlled study, there was no detectable effect on growth or sexual maturation in the adolescent boys or girls, or any effect on menstrual cycle length in girls. (see sections 4.2 and 4.8). EZETROL has not been studied in patients younger than 10 years of age or in pre-menarchal girls.

**4.5 Interaction with other medicines and other forms of interaction**

In preclinical studies, it has been shown that ezetimibe does not induce cytochrome P450 medicine metabolising enzymes. No clinically significant pharmacokinetic interactions have been observed between ezetimibe and medicines known to be metabolised by cytochromes P450 1A2, 2D6, 2C8, 2C9, and 3A4, or N-acetyltransferase.

Ezetimibe had no effect on the pharmacokinetics of dapsone, dextromethorphan, digoxin, oral contraceptives (ethinyl estradiol and levonorgestrel), glipizide, tolbutamide, or midazolam during co-administration. Cimetidine, co-administered with ezetimibe, had no effect on the bioavailability of ezetimibe.

**Antacids:** Concomitant antacid administration decreased the rate of absorption of ezetimibe but had no effect on the bioavailability of ezetimibe. This decreased rate of absorption is not considered clinically significant.

**Cholestyramine:** Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe (ezetimibe + ezetimibe glucuronide) approximately 55%. The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be lessened by this interaction.

**Cyclosporine:** In a study of eight post-renal transplant patients with creatinine clearance of >50 mL/min on a stable dose of cyclosporine, a single 10 mg dose of ezetimibe resulted in a 3.4-fold (range 2.3- to 7.9-fold) increase in the mean AUC for total ezetimibe compared to a healthy control population from another study (n=17). In a different study, a renal transplant patient with severe renal insufficiency (creatinine clearance of 13.2 mL/min/1.73 m²) who was receiving multiple medications, including cyclosporine, demonstrated a 12-fold greater exposure to total ezetimibe compared to concurrent controls. In a two-period crossover study in twelve healthy subjects, daily administration of 20 mg ezetimibe for 8 days with a single 100 mg dose of cyclosporine on Day 7 resulted in a mean 15% increase in cyclosporine AUC (range 10% decrease to 51% increase) compared to a single 100 mg dose of cyclosporine alone (see section 4.4).
Fibrates: Concomitant fenofibrate or gemfibrozil administration increased total ezetimibe concentrations approximately 1.5- and 1.7-fold respectively, however these increases are not considered clinically significant. The safety and effectiveness of ezetimibe administered with fibrates have not been established. Fibrates may increase cholesterol excretion into the bile, leading to cholelithiasis. In a preclinical study in dogs, ezetimibe (≥0.03 mg/kg/day) increased cholesterol in the gallbladder bile ~2- to 3-fold. Although the relevance of this preclinical finding to humans is unknown, coadministration of EZETROL with fibrates is not recommended until use in patients is studied.

Statins: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, or rosuvastatin.

Anticoagulants: Concomitant administration of ezetimibe (10 mg once daily) had no significant effect on bioavailability of warfarin and prothrombin time in a study of twelve healthy adult males. There have been post-marketing reports of increased International Normalised Ratio in patients who had EZETROL added to warfarin or fluindione. Most of these patients were also on other medications (See section 4.4).

4.6 Fertility, pregnancy and lactation

Pregnancy
No clinical data on exposed pregnancies are available. Animal studies of ezetimibe administered alone do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). However, caution should be exercised when prescribing to pregnant women.

When ezetimibe was given with lovastatin, simvastatin, pravastatin or atorvastatin, no teratogenic effects were observed in embryo-foetal development studies in pregnant rats. In pregnant rabbits, a low incidence of skeletal malformations was observed (see section 5.3).

When ezetimibe is to be administered with a statin, please refer to the data sheet for that particular statin.

Breast-feeding
Studies in rats have shown that ezetimibe is excreted in milk. It is not known whether ezetimibe is excreted into human breast milk, therefore, EZETROL should not be used in nursing mothers unless the potential benefit justifies the potential risk to the infant.

Fertility
No clinical trial data are available on the effects of ezetimibe on human fertility. Ezetimibe had no effect on the fertility of male or female rats (see section 5.3).

4.7 Effects on ability to drive and use machines
No studies of the effects on the ability to drive and use of machines have been performed. However, certain side effects that have been reported with EZETROL may affect some patients’ ability to drive or operate machinery. Individual responses to EZETROL may vary. (see section 4.8).
4.8 Undesirable effects
Clinical studies of up to 112 weeks duration in which EZETROL 10 mg daily was administered alone (n=2396), or with a statin (n=11,308), patients demonstrated: EZETROL was generally well tolerated, adverse reactions were usually mild and transient, the overall incidence of side effects reported with EZETROL was similar to that reported with placebo, and the discontinuation rate due to adverse experiences was comparable between EZETROL and placebo.

The following common (≥1/100, <1/10) or uncommon (≥1/1,000, <1/100); medicine-related adverse experiences were reported in patients taking EZETROL alone (n = 2396) and at a greater incidence than placebo (n=1159), or in patients taking EZETROL co-administered with a statin (n = 11,308) and at a greater incidence than statin administered alone (n=9361):

EZETROL administered alone:

Investigations:
Uncommon: ALT and/or AST increased; blood CPK increased; gamma-glutamyltransferase increased; liver function test abnormal

Respiratory, Thoracic and Mediastinal Disorders:
Uncommon: cough

Gastrointestinal Disorders:
Common: abdominal pain; diarrhoea; flatulence
Uncommon: dyspepsia; gastroesophageal reflux disease; nausea

Musculoskeletal and Connective Tissue Disorders
Uncommon: arthralgia; muscle spasms; neck pain

Metabolism and Nutrition Disorders:
Uncommon: decreased appetite

Vascular Disorders:
Uncommon: hot flush; hypertension

General Disorders and Administration Site Condition:
Common: fatigue
Uncommon: chest pain; pain

EZETROL co-administered with a statin:

Investigations:
Common: ALT and/or AST increased

Nervous System Disorders:
Common: headache
Uncommon: paresthesia
Gastrointestinal Disorders:  
*Uncommon*: dry mouth; gastritis

Skin and Subcutaneous Tissue Disorders:  
*Uncommon*: pruritus; rash; urticaria

Musculoskeletal and Connective Tissue Disorders:  
*Common*: myalgia  
*Uncommon*: back pain; muscular weakness; pain in extremity

General Disorders and Administration Site Condition:  
*Uncommon*: asthenia; oedema peripheral

Patients with Coronary Heart Disease  
In the IMPROVE-IT study, involving 18,144 patients treated with either ezetimibe/simvastatin 10/40 mg (n=9067; of whom 6% were uptitrated to ezetimibe/simvastatin 10/80 mg) or simvastatin 40 mg (n=9077; of whom 27% were uptitrated to simvastatin 80 mg), the safety profiles were similar during a median follow-up period of 6.0 years. Discontinuation rates due to adverse experiences were 10.6% for patients treated with ezetimibe/simvastatin and 10.1% for patients treated with simvastatin. The incidence of myopathy was 0.2% for ezetimibe/simvastatin and 0.1% for simvastatin, where myopathy was defined as unexplained muscle weakness or pain with a serum CK ≥10 times ULN or two consecutive observations of CK ≥5 and <10 times ULN. The incidence of rhabdomyolysis was 0.1% for ezetimibe/simvastatin and 0.2% for simvastatin, where rhabdomyolysis was defined as unexplained muscle weakness or pain with a serum CK ≥10 times ULN with evidence of renal injury, ≥5 X ULN and <10 X ULN on two consecutive occasions with evidence of renal injury or CK ≥10,000 IU/L without evidence of renal injury. The incidence of consecutive elevations of transaminases (≥3 X ULN) was 2.5% for ezetimibe/simvastatin and 2.3% for simvastatin. (see section 4.4.) Gallbladder-related adverse effects were reported in 3.1% vs 3.5% of patients allocated to ezetimibe/simvastatin and simvastatin, respectively. The incidence of cholecystectomy hospitalizations was 1.5% in both treatment groups. Cancer (defined as any new malignancy) was diagnosed during the trial in 9.4% vs 9.5%, respectively.

Patients with Chronic Kidney Disease  
In the Study of Heart and Renal Protection (SHARP) (see section 5.1), involving over 9000 patients treated with a fixed dose combination of EZETROL 10 mg with simvastatin 20 mg daily (n=4650) or placebo (n=4620), the safety profiles were comparable during a median follow-up period of 4.9 years. In this trial, only serious adverse events and discontinuations due to any adverse events were recorded. Discontinuation rates due to adverse events were comparable (10.4% in patients treated with EZETROL combined with simvastatin, 9.8% in patients treated with placebo). The incidence of myopathy/rhabdomyolysis was 0.2% in patients treated with EZETROL combined with simvastatin and 0.1% in patients treated with placebo. Consecutive elevations of transaminases (> 3X ULN) occurred in 0.7% of patients treated with EZETROL combined with simvastatin compared with 0.6% of patients treated with placebo (see section 4.4 ). In this trial, there were no statistically significant increases in the incidence of pre-specified adverse events, including cancer (9.4% for EZETROL combined with simvastatin, 9.5% for placebo), hepatitis, cholecystectomy or complications of gallstones or pancreatitis.
In a study involving adolescent (10 to 17 years of age) patients with heterozygous familial hypercholesterolaemia (n = 248), the safety and tolerability profile of the group co-administered EZETROL and simvastatin was similar to that of adult patients co-administered EZETROL and simvastatin (see section 4.4).

**Laboratory Test Findings**
In controlled clinical monotherapy trials, the incidence of clinically important elevations in serum transaminases (ALT and/or AST ≥ 3 X ULN, consecutive) was similar between EZETROL (0.5 %) and placebo (0.3 %). In co-administration trials, the incidence was 1.3% for patients treated with EZETROL co-administered with a statin and 0.4% for patients treated with a statin alone. These elevations were generally asymptomatic, not associated with cholestasis, and returned to baseline after discontinuation of therapy or with continued treatment (see section 4.4).

Clinically important elevations of CPK (≥10 X ULN) in patients treated with EZETROL administered alone or co-administered with a statin were similar to elevations seen with placebo or statin administered alone, respectively.

In a study involving adolescent (10 to 17 years of age) patients with heterozygous familial hypercholesterolaemia (n = 248), elevations of CPK (≥10 X ULN) occurred in two patients (2%) treated with EZETROL plus simvastatin and in zero patients treated with simvastatin alone. No cases of myopathy were reported.

**Post-Marketing Experience**
The following adverse reactions have been reported in post-marketing experience, regardless of causality assessment:

- **Blood and lymphatic system disorders:** thrombocytopenia
- **Nervous system disorders:** dizziness; paraesthesia
- **Gastrointestinal disorders:** pancreatitis; constipation
- **Skin and subcutaneous tissue disorders:** erythema multiforme
- **Musculoskeletal and connective tissue disorders:** myalgia; myopathy/rhabdomyolysis (see section 4.4)
- **General disorders and administration site conditions:** asthenia
- **Immune system disorders:** Hypersensitivity reactions, including anaphylaxis, angioedema, rash, and urticaria
- **Hepatobiliary disorders:** hepatitis; cholelithiasis; cholecystitis
- **Psychiatric disorders:** depression

**Reporting of suspected adverse reactions**
Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/)

**4.9 Overdose**
In clinical studies, administration of ezetimibe, 50 mg/day to 15 healthy subjects for up to 14 days, 40 mg/day to 18 patients with primary hypercholesterolaemia for up to 56 days, and 40 mg/day to 27 patients with homozygous sitosterolaemia for 26 weeks, was generally well tolerated.
A few cases of over dosage with ezetimibe have been reported; most have not been associated with adverse experiences. Reported adverse experiences have not been serious. In the event of an overdose, symptomatic and supportive measures should be employed.

For advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other lipid modifying agents, ATC code: C10A X09

Ezetimibe is described chemically as 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C$_{24}$H$_{21}$F$_{2}$NO$_{3}$. Its molecular weight is 409.4 and its structural formula is:

![Ezetimibe Structural Formula]

Ezetimibe is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water. Ezetimibe has a melting point of about 163°C and is stable at ambient temperature.

Mechanism of action

EZETROL is in a new class of lipid-lowering compounds that selectively inhibit the intestinal absorption of cholesterol and related plant sterols. EZETROL is orally active and potent, with a unique mechanism of action that differs from other classes of cholesterol-reducing compounds (e.g., statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol and plant sterols.

Ezetimibe localises at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood. Ezetimibe does not increase bile acid excretion (like bile acid sequestrants) and does not inhibit cholesterol synthesis in the liver (like statins).

In a 2-week clinical study in 18 hypercholesterolaemic patients, EZETROL inhibited intestinal cholesterol absorption by 54 %, compared with placebo. By inhibiting the absorption of intestinal cholesterol, ezetimibe reduces the delivery of cholesterol to the liver. Statins reduce cholesterol synthesis in the liver. Together these distinct mechanisms provide complementary cholesterol reduction. EZETROL, administered with a statin, reduces total-C, LDL-C, Apo B, and TG and
increases HDL C in patients with hypercholesterolaemia, beyond either treatment alone.

Clinical studies demonstrate that elevated levels of total-C, LDL-C and Apo B, the major protein constituent of LDL, promote human atherosclerosis. In addition, decreased levels of HDL-C are associated with the development of atherosclerosis. Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and remnants, can also promote atherosclerosis.

**Pharmacodynamic effects**

A series of preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting cholesterol absorption. Ezetimibe inhibited the absorption of \[^{14}\text{C}\]-cholesterol with no effect on the absorption of triglycerides, fatty acids, bile acids, progesterone, ethinyl estradiol, or the fat soluble vitamins A and D.

Epidemiologic studies have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C.

**Clinical efficacy and safety**

*Prevention of Major Vascular Events in Chronic Kidney Disease (CKD)*

The Study of Heart and Renal Protection (SHARP) was a multinational, randomised, placebo-controlled, double-blind study conducted in 9,438 patients with chronic kidney disease, a third of whom were on dialysis at baseline. Patients with a definite history of myocardial infarction (MI) or coronary revascularisation procedure, existing or planned renal transplant, recent acute uraemic emergency, evidence of active inflammatory muscle disease or creatine kinase (CK) >3xULN were excluded. For the first year, patients were randomised in a ratio of 4:4:1, respectively, to a fixed dose combination of EZETROL 10 mg with simvastatin 20 mg, placebo, or simvastatin 20 mg daily. The 1-year simvastatin arm was included to enable the comparison of EZETROL combined with simvastatin to simvastatin alone with regard to safety and lipids. At 1 year the simvastatin-only arm was re-randomised 1:1 to a fixed dose combination of EZETROL 10 mg with simvastatin 20 mg or placebo. A total of 4,650 patients were allocated to EZETROL 10 mg combined with simvastatin 20 mg and 4,620 to placebo, and followed for a median of 4.9 years. Patients had a mean age of 62 (ranging in age from 39 to 94.5 years old); 63% were male, 72% were Caucasian and 23% were diabetic; and, for those not on dialysis, the median serum creatinine was 0.22 mmol/L and the mean estimated glomerular filtration rate (eGFR) was 26.5 mL/min/1.73 m\(^2\), with 94% of patients having an eGFR < 45 mL/min/1.73 m\(^2\). There were no lipid entry criteria. Mean LDL-C at baseline was 2.8 mmol/L. As of the 1-year measurement, LDL-C was reduced 26% relative to placebo by simvastatin 20 mg alone and 38% for EZETROL 10 mg combined with simvastatin 20 mg. At the midpoint of the study (2.5 years) mean LDL-C reduction in all randomised patients for EZETROL combined with simvastatin relative to placebo was 32%. All lipid measurements included patients no longer taking study medication.

The SHARP protocol-specified primary comparison was an intention-to-treat analysis of "major vascular events" (MVE; defined as nonfatal MI or cardiac death, stroke, or any revascularisation procedure) in only those patients initially randomised to the EZETROL combined with simvastatin (n=4,193) or placebo (n=4,191) groups. Secondary analyses included the same composite analysed for the full cohort randomised (at study baseline or at year 1) to EZETROL combined with simvastatin (n=4,650) or placebo (n=4,620) as well as the components of this composite.
The primary endpoint analysis showed that EZETROL combined with simvastatin significantly reduced the risk of MVE (749 patients with events in the placebo group vs. 639 in the EZETROL combined with simvastatin group) with an absolute risk reduction of 2.3% (number needed to treat, 43) and a relative risk reduction of 16% (p=0.001) (see Figure 1). An analysis of major atherosclerotic events (MAE, a subset of the MVE composite that excluded non-coronary cardiac deaths and haemorrhagic stroke) showed that EZETROL combined with simvastatin significantly reduced the risk of MAE (526 (11.3%) of 4650 patients ever allocated to EZETROL combined with simvastatin and 619 (13.4%) of 4620 patients ever allocated to placebo), corresponding to an absolute risk reduction of 2.1% (number needed to treat, 48) and a relative risk reduction of 17% (p=0.002).

The risk reduction for the MVE composite was directionally consistent (i.e., EZETROL combined with simvastatin numerically superior to placebo) with that of the entire cohort of patients for the following key baseline predefined subgroups: age, gender, dialysis vs. non-dialysis, eGFR, diabetes, pre-existing atherosclerotic disease, blood pressure, or tertiles of baseline LDL-C.

Compliance rates with placebo and study medication declined over the course of the study. For example, at 20-25 months of follow-up, 68% of patients allocated to ezetimibe/simvastatin and 67% of patients allocated to placebo were taking 80% or more of the study medication, while at 44-49 months, compliance had fallen to 60% and 56%, respectively.

Figure 1: Effect of EZETROL Combined with Simvastatin on the Primary Endpoint of Risk of Major Vascular Events

The individual components of MVE in all randomised patients are presented in Table 1. EZETROL combined with simvastatin significantly reduced the risk of stroke and any revascularisation, with non-significant numerical differences favouring EZETROL combined with simvastatin for nonfatal MI and cardiac death.
Table 1: Major Vascular Events by Treatment Group in All Randomised Patients in SHARP\textsuperscript{a}

<table>
<thead>
<tr>
<th>Outcome</th>
<th>EZETROL 10 mg combined with simvastatin (N=4,650)</th>
<th>Placebo (N=4,620)</th>
<th>Risk Ratio (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Major Vascular Events</td>
<td>701 (15.1%)</td>
<td>814 (17.6%)</td>
<td>0.85 (0.77-0.94)</td>
<td>0.001</td>
</tr>
<tr>
<td>Nonfatal MI</td>
<td>134 (2.9%)</td>
<td>159 (3.4%)</td>
<td>0.84 (0.66-1.05)</td>
<td>0.12</td>
</tr>
<tr>
<td>Cardiac Death</td>
<td>253 (5.4%)</td>
<td>272 (5.9%)</td>
<td>0.93 (0.78-1.10)</td>
<td>0.38</td>
</tr>
<tr>
<td>Any Stroke</td>
<td>171 (3.7%)</td>
<td>210 (4.5%)</td>
<td>0.81 (0.66-0.99)</td>
<td>0.038</td>
</tr>
<tr>
<td>Non-haemorrhagic Stroke</td>
<td>131 (2.8%)</td>
<td>174 (3.8%)</td>
<td>0.75 (0.60-0.94)</td>
<td>0.011</td>
</tr>
<tr>
<td>Haemorrhagic Stroke</td>
<td>45 (1.0%)</td>
<td>37 (0.8%)</td>
<td>1.21 (0.78-1.86)</td>
<td>0.40</td>
</tr>
<tr>
<td>Any Revascularisation</td>
<td>284 (6.1%)</td>
<td>352 (7.6%)</td>
<td>0.79 (0.68-0.93)</td>
<td>0.004</td>
</tr>
<tr>
<td>Major Atherosclerotic Events (MAE)\textsuperscript{b}</td>
<td>526 (11.3%)</td>
<td>619 (13.4%)</td>
<td>0.83 (0.74-0.94)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Intention-to-treat analysis on all SHARP patients randomised to EZETROL combined with simvastatin or placebo either at baseline or year 1.

\textsuperscript{b} MAE defined as the composite of nonfatal myocardial infarction, coronary death, non-haemorrhagic stroke, or any revascularisation.

No significant treatment effect of EZETROL combined with simvastatin on MVE was found in the subgroup of patients on dialysis at baseline compared with those not on dialysis at baseline. Among 3023 patients on dialysis at baseline, EZETROL combined with simvastatin reduced the risk of MVE by 6% (RR 0.94: 95% CI 0.80-1.09) compared with 22% (RR 0.78: 95% CI 0.69-0.89) among 6247 patients not on dialysis at baseline (interaction P=0.08).

Among patients not on dialysis at baseline, EZETROL combined with simvastatin did not reduce the risk of progressing to end-stage renal disease compared with placebo.

There were no significant differences between the EZETROL combined with simvastatin and placebo groups on all cause mortality, or on any specific cause of death.

The study design precluded drawing conclusions regarding the independent contribution of either ezetimibe or simvastatin to the observed effect, and was not able to provide evidence of efficacy for the combination of EZETROL 10 mg with simvastatin 20 mg compared to either the lower dose combination (i.e. EZETROL 10 mg with simvastatin 10 mg) or to treatment with statin alone (i.e. simvastatin 20 mg).

The effect of ezetimibe taken in combination with other statins in patients with CKD has not been studied.
5.2 Pharmacokinetic properties

Absorption
After oral administration, ezetimibe is rapidly absorbed and extensively conjugated to a pharmacologically active phenolic glucuronide (ezetimibe-glucuronide). Mean maximum plasma concentrations (C\text{max}) occur within 1 to 2 hours for ezetimibe-glucuronide and 4 to 12 hours for ezetimibe. The absolute bioavailability of ezetimibe cannot be determined as the compound is virtually insoluble in aqueous media suitable for injection.

Concomitant food administration (high fat or non-fat meals) had no effect on the oral bioavailability of ezetimibe when administered as EZETROL 10 mg tablets. EZETROL can be administered with or without food.

Distribution
Ezetimibe and ezetimibe-glucuronide are bound 99.7% and 88 to 92% to human plasma proteins, respectively.

Biotransformation
Ezetimibe is metabolised primarily in the small intestine and liver via glucuronide conjugation (a phase II reaction) with subsequent biliary excretion. Minimal oxidative metabolism (a phase I reaction) has been observed in all species evaluated. Ezetimibe and ezetimibe-glucuronide are the major medicine-derived compounds detected in plasma, constituting approximately 10 to 20 % and 80 to 90 % of the total medicine in plasma, respectively. Both ezetimibe and ezetimibe-glucuronide are slowly eliminated from plasma with evidence of significant enterohepatic recycling. The half-life for ezetimibe and ezetimibe-glucuronide is approximately 22 hours.

Elimination
Following oral administration of \textsuperscript{14}C-ezetimibe (20 mg) to human subjects, total ezetimibe accounted for approximately 93 % of the total radioactivity in plasma. Approximately 78 % and 11 % of the administered radioactivity were recovered in the faeces and urine, respectively, over a 10-day collection period. After 48 hours, there were no detectable levels of radioactivity in the plasma.

Characteristics in Patients (Special Populations)

Paediatric Patients
The absorption and metabolism of ezetimibe are similar between children and adolescents (10 to 18 years) and adults. Based on total ezetimibe, there are no pharmacokinetic differences between adolescents and adults. Pharmacokinetic data in the paediatric population <10 years of age are not available.

Geriatric Patients
Plasma concentrations for total ezetimibe are about 2-fold higher in the elderly (≥65 years) than in the young (18 to 45 years). LDLC reduction and safety profile are comparable between elderly and young subjects treated with EZETROL. Therefore, no dosage adjustment is necessary in the elderly.

Hepatic Insufficiency
After a single 10 mg dose of ezetimibe, the mean area under the curve (AUC) for total ezetimibe was increased approximately 1.7-fold in patients with mild hepatic insufficiency (Child Pugh score 5 or 6), compared to healthy subjects. In a 14-day, multiple-dose study (10 mg daily) in patients with
moderate hepatic insufficiency (Child Pugh score 7 to 9), the mean AUC for total ezetimibe was increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects. No dosage adjustment is necessary for patients with mild hepatic insufficiency. Due to the unknown effects of the increased exposure to ezetimibe in patients with moderate or severe (Child Pugh score >9) hepatic insufficiency, ezetimibe is not recommended in these patients (see section 4.4).

Renal Insufficiency
After a single 10 mg dose of ezetimibe in patients with severe renal disease (n=8; mean CrCl ≤30 mL/min/1.73m²), the mean AUC for total ezetimibe was increased approximately 1.5-fold, compared to healthy subjects (n=9). This result is not considered clinically significant. No dosage adjustment is necessary for renally impaired patients.

An additional patient in this study (post-renal transplant and receiving multiple medications, including cyclosporine) had a 12-fold greater exposure to total ezetimibe.

Gender
Plasma concentrations for total ezetimibe are slightly higher (<20%) in women than in men. LDL-C reduction and safety profile are comparable between men and women treated with ezetimibe. Therefore, no dosage adjustment is necessary on the basis of gender.

Race
Based on a meta-analysis of pharmacokinetic studies, there were no pharmacokinetic differences between Blacks and Caucasians.

5.3 Preclinical safety data
Acute Toxicity
In animals, no toxicity was observed after single oral doses of 5000 mg/kg of ezetimibe in rats and mice and 3000 mg/kg in dogs.

Chronic Toxicity
Ezetimibe was well tolerated by mice, rats and dogs. No target organs of toxicity were identified in chronic studies at daily doses up to 1500 (males) and 500 mg/kg (females) in rats, up to 500 mg/kg in mice, or up to 300 mg/kg in dogs.

The safety of concomitant administration of ezetimibe and statins was assessed in rats and dogs. When ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin or lovastatin, for three months, toxicologic findings were consistent with those seen with statins administered alone.

Carcinogenicity
In two-year studies conducted in mice and rats, ezetimibe was not carcinogenic.

Mutagenesis
Ezetimibe was not genotoxic in a series of in vivo and in vitro tests.

Combinations of ezetimibe with atorvastatin, simvastatin, pravastatin, or lovastatin were not genotoxic in a series of in vitro and in vivo assays.
Reproduction
Ezetimibe did not affect the fertility of male or female rats.

Development
Ezetimibe was not teratogenic in rats or rabbits and had no effect on prenatal or postnatal development.

Concomitant administration of ezetimibe and statins was not teratogenic in rats. In pregnant rabbits, a low incidence of skeletal malformations (fused sternebrae, fused caudal vertebrae, reduced number of caudal vertebrae) was observed when ezetimibe (1000 mg/kg; ≥146 times the human exposure at 10 mg daily based on AUC\textsubscript{0-24hr} for total ezetimibe) was administered with lovastatin (2.5 and 25 mg/kg), simvastatin (5 and 10 mg/kg), pravastatin (25 and 50 mg/kg), or atorvastatin (5, 25, and 50 mg/kg). Exposure to the pharmacologically active form of the statin ranged from 1.4 (atorvastatin) to 547 (lovastatin) times the human exposure at 10 mg daily (simvastatin or atorvastatin) or 20 mg daily (lovastatin and pravastatin) based on AUC\textsubscript{0-24hr}.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients
Croscarmellose sodium
Lactose monohydrate
Magnesium stearate
Microcrystalline cellulose
Povidone
Sodium laurilsulfate

6.2 Incompatibilities
Not applicable.

6.3 Shelf life
3 years.

6.4 Special precautions for storage
Store below 30°C. Store in the original package.

6.5 Nature and contents of container
EZETROL 10 mg, tablets are available in packs of 30.

6.6 Special precautions for disposal
No special requirements.

7 MEDICINE SCHEDULE
Prescription Medicine
8 SPONSOR
Merck Sharp & Dohme (New Zealand) Limited
P O Box 99 851
Newmarket
Auckland
NEW ZEALAND
Tel: 0800 500 673

9 DATE OF FIRST APPROVAL
23rd April 2003.

10 DATE OF REVISION OF THE TEXT
16 Nov 2017

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Date</th>
<th>Section(s) changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td>16 Nov 2017</td>
<td>-</td>
<td>Update to new SPC-style format</td>
</tr>
<tr>
<td></td>
<td>4.4 &amp; 4.8</td>
<td>Update to precautions and AE information to include safety information related to IMPROVE-IT clinical trial (WPC-MK0653-T-032015 and -102015).</td>
</tr>
</tbody>
</table>